Invivo Therapeutics Holdings Stock Fundamentals
NVIVDelisted Stock | USD 1.38 0.07 5.34% |
InVivo Therapeutics Holdings fundamentals help investors to digest information that contributes to InVivo Therapeutics' financial success or failures. It also enables traders to predict the movement of InVivo Stock. The fundamental analysis module provides a way to measure InVivo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to InVivo Therapeutics stock.
InVivo |
InVivo Therapeutics Holdings Company Return On Equity Analysis
InVivo Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current InVivo Therapeutics Return On Equity | -0.98 |
Most of InVivo Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InVivo Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, InVivo Therapeutics Holdings has a Return On Equity of -0.9811. This is 95.91% lower than that of the Health Care Equipment & Supplies sector and 97.31% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
InVivo Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining InVivo Therapeutics's current stock value. Our valuation model uses many indicators to compare InVivo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across InVivo Therapeutics competition to find correlations between indicators driving InVivo Therapeutics's intrinsic value. More Info.InVivo Therapeutics Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value InVivo Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.InVivo Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InVivo Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InVivo Therapeutics could also be used in its relative valuation, which is a method of valuing InVivo Therapeutics by comparing valuation metrics of similar companies.InVivo Therapeutics is currently under evaluation in return on equity category among its peers.
InVivo Fundamentals
Return On Equity | -0.98 | |||
Return On Asset | -0.54 | |||
Current Valuation | (7.59 M) | |||
Shares Outstanding | 3.11 M | |||
Shares Owned By Insiders | 0.02 % | |||
Shares Owned By Institutions | 3.44 % | |||
Number Of Shares Shorted | 17.63 K | |||
Price To Earning | (1.90) X | |||
Price To Book | 0.1 X | |||
EBITDA | (9.8 M) | |||
Net Income | (9.33 M) | |||
Cash And Equivalents | 13.03 M | |||
Cash Per Share | 9.36 X | |||
Total Debt | 949 K | |||
Debt To Equity | 0.09 % | |||
Current Ratio | 5.64 X | |||
Book Value Per Share | 2.87 X | |||
Cash Flow From Operations | (10.13 M) | |||
Short Ratio | 0.91 X | |||
Earnings Per Share | (3.28) X | |||
Target Price | 37.5 | |||
Beta | 0.66 | |||
Market Capitalization | 995.92 K | |||
Total Asset | 18.82 M | |||
Retained Earnings | (248.62 M) | |||
Working Capital | 15.13 M | |||
Current Asset | 20.74 M | |||
Current Liabilities | 3.31 M | |||
Z Score | -18.62 | |||
Net Asset | 18.82 M |
About InVivo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze InVivo Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InVivo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InVivo Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. Invivo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |